Volume : 08, Issue : 06, June – 2021
Title:
08.STUDY AND REVIEW OF ROLE OF PHARMACOGENOMICS IN NEW DRUG DISCOVERY
Authors :
Suwarna Patil, Prof. Mazharoddin Nizamoddin, Prof. U. H. Patil
Abstract :
Drug development can be facilitated by genetic and genomic knowledge. Pharmacogenomics is the branch of pharmacology which deals with the influence of genetic variation on drug response in patients by correlating gene expression or single-nucleotide polymorphisms with a drug’s efficacy or toxicity. It aims to develop rational means to optimize drug therapy, with respect to the patient’s genotype, to ensure maximum efficacy with minimal adverse effects. Pharmacogenomics is the whole genome application of pharmacogenetics, which examines the single gene interactions with drugs. Here, we review the contribution of genomics for understanding the biological relevance of a drug target, such approaches promise the advent of ‘personalized medicine’, in which drugs and drug combinations are optimized for each individual’s unique genetic makeup.
Cite This Article:
Please cite this article in press Suwarna Patil et al., Study And Review Of Role Of Pharmacogenomics In New Drug Discovery.., Indo Am. J. P. Sci, 2021; 08(06).
Number of Downloads : 10
References:
1. Holbein, M.E. Understanding FDA regulatory requirements for investigational new drug applications for sponsor-investigators. J. Investig. Med. 2009, 57, 688–694.
2. Telenti, A.; Pierce, L.C.; Biggs, W.H.; di Iulio, J.; Wong, E.H.; Fabani, M.M.; Kirkness, E.F.; Moustafa, A.;Shah, N.; Xie, C.; et al. Deep sequencing of 10,000 human genomes. Proc. Natl. Acad. Sci. USA 2016, 113,11901–11906.
3. Plenge, R.M.; Scolnick, E.M.; Altshuler, D. Validating therapeutic targets through human genetics. Nat. Rev.Drug Discov. 2013, 12, 581–594.
4. Giral, H.; Landmesser, U.; Kratzer, A. Into theWild: GWASExploration of Non-coding RNAs. Front. Cardiovasc. 2018, 5181.
5. King, E.A.; Davis, J.W.; Degner, J.F. Are drug targets with genetic support twice as likely to be approved Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. PLoS Genet. 2019, 15, e1008489.
6. Rentzsch, P.;Witten, D.; Cooper, G.M.; Shendure, J.; Kircher, M. CADD: Predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res. 2019, 47, D886–D894.
7. Bartha, I.; di Iulio, J.; Venter, J.C.; Telenti, A. Human gene essentiality. Nat. Rev. Genet. 2018, 19, 51–62.
8. Lek, M.; Karczewski, K.J.; Minikel, E.V.; Samocha, K.E.; Banks, E.; Fennell, T.; O’Donnell-Luria, A.H.;Ware, J.S.; Hill, A.J.; Cummings, B.B.; et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 2016, 536, 285–291.
9. Rausell, A.; Luo, Y.; Lopez, M.; Seeleuthner, Y.; Rapaport, F.; Favier, A.; Stenson, P.D.; Cooper, D.N.; Patin, E.; Casanova, J.L.; et al. Common homozygosity for predicted loss-of-function variants reveals both redundant and advantageous e_ects of dispensable human genes. Proc. Natl. Acad. Sci. USA 2020, 117, 13626–13636.
10. Karczewski, K.J.; Francioli, L.C.; Tiao, G.; Cummings, B.B.; Alfoldi, J.;Wang, Q.; Collins, R.L.; Laricchia, K.M.; Ganna, A.; Birnbaum, D.P.; et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 2020, 581, 434–443.
11. Fiers W, Contreras R, Duerinck F, Haegeman G, Iserentant D, Merregaert J, Min Jou W, et al. Complete nucleotide sequence of bacteriophage MS2 RNA: primary and secondary structure of the replicase gene. Nature 1976;260(5551):500-507.
12. Sanger F, Air GM, Barrell BG, Brown NL, Coulson AR, Fiddes CA, Hutchison CA, et al. Nucleotide sequence of bacteriophage phi X174 DNA. Nature 1977;265(5596):687-695.
13. Min Jou W, Haegeman G, Ysebaert M, Fiers W. Nucleotide sequence of the gene coding for the bacteriophage MS2 coat protein. Nature 1972;237(5350):82-88.
14. The Viral Genomes Resource, NCBI Friday,14 September 2007. Genome Project Statistic , NCBI Friday,14 September 2007.
15. Emsley RA. Partial response to antipsychotic treatment: the patient with enduring symptoms. J Clin Psychiatry 1999;60 Suppl 23(10-13.
16. Lu AY. Drug-metabolism research challenges in the new millennium: individual variability in drug therapy and drug safety. Drug Metab Dispos 1998;26(12):1217-
1222.
17. Pistoi.S. Facing your genetic destiny, part II. Scientifi American. February 25, 2002.9(15):1200-5.
18. 1Magdum C.S., Velingkar V.S. and Meenu K.Gupta Pharmacogenomics:The search for the Individualized Therapy, Indian Journal of Pharmaceutical Education &Research 40(2) April-June 2006,page no:84-91.
19. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279(15):1200-1205.
20. Roberto Spreafico , Leah B. Soriaga, Johannes Grosse, HerbertW. Virgin and Amalio Telenti, Advances in Genomics for Drug Development, Genes 2020
21. Aneesh T Pa, b, Sonal Sekhar Ma, Asha Josea, Lekshmi Chandrana, Subin Mary Zachariaha, Pharmacogenomics: The Right Drug to the Right Person, Journal of Clinical Medical Research, October 2009.